Overview

Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis

Status:
Completed
Trial end date:
2019-03-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine changes in immune cells and proteins in response to treatment with two approved therapies for Rheumatoid arthritis (RA), abatacept versus adalimumab, both given in combination with methotrexate.
Phase:
Phase 4
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Abatacept
Adalimumab
Antirheumatic Agents
Methotrexate